Supreme Court to tackle gene patent case

The U.S. Supreme Court is going to take up a case that could have a major impact on the patentability of genes used in diagnostics. The Supreme Court will review a case concerning Myriad Genetics ($MYGN), which won a decision from the U.S. Court of Appeals for the Federal Circuit in August. Myriad and other companies seeking novel genetic findings say that patents are important to protecting their investments in innovation. We'll see what the justices think about it. Article



Sponsored By Paraza Pharma

Choosing the Right Pre-Clinical Collaborative Research Organization (CRO)

Learn about the key factors that are essential to creating a collaborative and productive working relationship to advance pre-clinical drug discovery programs.